69821-05-2

Usage

Explanation

The compound's name is derived from its structure, which includes a bromine atom at the 1st position, methoxy groups at the 2nd and 5th positions, and methyl groups at the 3rd, 4th, and 6th positions on a benzene ring.

Explanation

The common name is not mentioned in the material, so the IUPAC name (1-bromo-2,5-dimethoxy-3,4,6-trimethylbenzene) is used.

Explanation

The chemical formula represents the compound's composition, with 11 carbon atoms, 17 hydrogen atoms, 1 bromine atom, and 2 oxygen atoms.

Explanation

The compound is in a liquid state and has no color.

Explanation

The compound has a noticeable and pleasant aroma.

Explanation

The compound is classified as a brominated aromatic compound due to the presence of a bromine atom attached to the benzene ring.

Explanation

The compound has various uses in the chemical industry, including the production of pharmaceuticals, agrochemicals, and other organic compounds. It also serves as a solvent and intermediate in the production of dyes and fragrances.

Explanation

The compound is considered hazardous and requires careful handling.

Explanation

Exposure to the compound can cause irritation to the skin, eyes, and respiratory system, emphasizing the need for proper handling and safety precautions.

Physical state

Colorless liquid

Odor

Strong, sweet

Classification

Brominated aromatic compound

Applications

Pharmaceutical and agrochemical production, synthesis of other organic compounds, solvent in chemical reactions, intermediate in the manufacture of dyes and fragrances

Hazardous nature

Yes

Health hazards

Irritation to skin, eyes, and respiratory system

Upstream product

• 39055-45-3 2-Bromo-3,5,6-trimethyl-hydroquinone 
• 77-78-1 dimethyl sulfate 
• 700-13-0 Trimethylhydroquinone 
• 4537-09-1 1,4-dimethoxy-2,3,5-trimethyl-benzene 

Downstream Products

• 129813-35-0 1-(2,5-Dimethoxy-3,4,6-trimethyl-phenyl)-1-pyridin-3-yl-propan-1-ol 
• 129813-36-1 1-(2,5-Dimethoxy-3,4,6-trimethyl-phenyl)-1-pyridin-3-yl-pentan-1-ol 
• 122115-62-2 3-(2,5-dimethoxy-3,4,6-trimethylphenyl)-1-butene 
• 89048-20-4 2,5-dimethoxy-3,4,6-trimethylbenzoic acid 
• 158720-03-7 1-(2-hydroxypropyl)-2,5-dimethoxy-3,4,6-trimethylbenzene 
• 357172-72-6 3-(2,5-Dimethoxy-3,4,6-trimethyl-phenyl)-1-((R)-2,2-dimethyl-[1,3]dioxolan-4-yl)-propan-1-one 
• 103187-96-8 1-benzyl-2,5-dimethoxy-3,4,6-trimethylbenzene 
• 103187-97-9 1-(4-methoxybenzyl)-2,5-dimethoxy-3,4,6-trimethylbenzene 
• 136702-44-8 (3R)-1-(2,5-dimethoxy-3,4,6-trimethylphenyl)-3-methyl-pentane-1ξ,3,5-triol 
• 216989-50-3 1-(2,5-dimethoxy-3,4,6-trimethylphenyl)-2-methyl-1-[4-(4-morpholinyl)phenyl]propan-1-ol 
• 96203-92-8 (E)-4-(2,5-dimethoxy-3,4,6-trimethylcyclohexa-1,5-dienyl)-2-methylbut-2-en-1-ol 
• 73892-12-3 (E)-1,4-dimethoxy-2,3,5-trimethyl-6-(3-methyl-4-(phenylsulfonyl)but-2-enyl)benzene 
• 158720-04-8 1‐allyl‐2,5‐dimethoxy‐3,4,6‐trimethylbenzene 
• 130627-52-0 (2’E,7’R,11‘R)-1-(2,5-dimethoxy-3,4,6-trimethylphenyl)-3,7,11,15-tetramethylhexadec-2-en-1-ol 

Relevant academic research and scientific papers

SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES

Methods of treating or suppressing oxidative stress diseases including mitochondrial diseases, impaired energy processing disorders, neurodegenerative diseases and diseases of aging are disclosed, as well as compounds useful in the methods of the invention, such as 2-substituted-p-quinone derivatives as disclosed herein.

Highly stereoselective construction of the C2 stereocentre of α-tocopherol (Vitamin E) by asymmetric addition of Grignard reagents to ketones

Tertiary alcohol precursors of both C2 diastereoisomers of α-tocopherol were prepared in three ways by our recently reported asymmetric Grignard synthesis. The versatility of Grignard chemistry inherent in its three-way disconnection was exploited to allow the synthesis of three product grades: 77:23 dr (5 steps), 81:19 dr (5 steps) and 96:4 dr (7 steps, one gram scale) from readily available and abundant starting materials. The products were converted to their respective α-tocopherols in 3 steps, which allowed a definitive re-assignment of their absolute configurations.

QUINONE BASED NITRIC OXIDE DONATING COMPOUNDS

The present invention relates to nitric oxide donor compounds having a quinone based structure, to processes for their preparation and to their use in the treatment and/or prophylaxis of glaucoma and ocular hypertension.

Total synthesis of (R, R, R)-γ-tocopherol through cu-catalyzed asymmetric 1,2-addition

Based on the asymmetric copper-catalyzed 1,2-addition of Grignard reagents to ketones, (R, R, R)-γ-tocopherol has been synthesized in 36% yield over 12 steps (longest linear sequence). The chiral center in the chroman ring was constructed with 73% ee by the 1,2-addition of a phytol-derived Grignard reagent to an a-bromo enone prepared from 2,3-dimethylquinone.

A new synthetic route to (S)-chroman aldehyde, a key chiral precursor of vitamin E

A highly stereocontrolled synthetic route to (S)-chroman aldehyde has been developed which starts with trimethyl-p-hydroquinone and (R)-glycerladehyde acetonide and employs as key steps the Michael addition of the aromatic copper species onto the (R)-4-acryloyl-1,3-dioxolane followed by the highly diastereoselective methylation of the resulting ketone adduct.

Electroorganic Synthesis, 58. Synthesis of Substituted Benzoquinones and their Use for Mediated Electrochemical Conversions

Hydroxy- (1a-3a) and hydroxyalkyl-substituted benzoquinones (6a-8a, 27a), suited to be immobilized by esterification with polyacrylic acid, are prepared.Their cathodic reduction potential Ep,c (1) correlates linearly with their substituent constant.The cathodic reduction of dioxygen and the palladium(II)-catalyzed anodic oxidation of alkenes are mediated by the benzoquinones 7b, 8b and 27b, respectively. - Key Words: Benzoquinones, substituted / Cyclic voltammetry / Cathodic dioxygen reduction, mediated / Anodic Wacker oxidation, mediated